---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-360059"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2026-08-21T13:10:29+00:00"
generated_at: "2026-08-21T13:12:09.717083+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Werewolf to merge with Ambros in reverse merger; Ambros valued at $500M, PIPE of $150M

## Summary
- Merger Sub to merge into Ambros; Ambros stockholders to own ~71.7% of combined company; Werewolf pre-merger holders ~6.8%.
- Concurrent PIPE financing of $150M from qualified investors; proceeds condition to close; implies Werewolf valuation $47.5M.
- Werewolf stockholders get CVRs for legacy WTX-124 and WTX-330 assets; no assurance of payments.
- Termination fees: $20M payable by Ambros in certain circumstances; $1.9M payable by Werewolf.
- Transaction requires stockholder approvals, S-4 filing, Nasdaq listing, and net cash condition; expected close not specified.

## SEC filing metadata
- accession: 0001193125-26-360059
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2026-08-21T13:10:29+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/0001193125-26-360059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-360059
- JSON: https://secwatch.observer/filing/0001193125-26-360059.json
- Plain text: https://secwatch.observer/filing/0001193125-26-360059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.